Keywords: Astellas, Ambit Biosciences, FLT3 kinase inhibitors, Licensing

Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million

Article | 18 December 2009

Leading Japanese drugmaker Astellas Pharma has entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in